Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells
Compose a Response to This Article
Other responses
No responses have been published for this article.
